Keyphrases
Non-vitamin K Antagonist Oral Anticoagulants
100%
Cerebral Venous Sinus Thrombosis
100%
Matched Cohort Analysis
100%
Vitamin K Antagonists
54%
Recanalization
36%
Major Bleeding
27%
Age-matched
27%
Modified Rankin Scale
27%
Tertiary Care Hospital
18%
Disability
18%
Randomized Controlled Trial
18%
Bleeding Complications
18%
Dabigatran
18%
Anticoagulant Use
18%
Multicenter Cohort Study
9%
No Significant Difference
9%
Clinical Features
9%
Heparin
9%
Lower Extremity Deep Venous Thrombosis
9%
Functional Outcome
9%
Follow-up Time
9%
Imaging Results
9%
University of Washington
9%
Anticoagulation
9%
Clot
9%
Intracranial Hemorrhage
9%
St. Louis
9%
School of Medicine
9%
University Schools
9%
Hemorrhagic Disease
9%
Historical Controls
9%
Rivaroxaban
9%
Demographic Risk Factors
9%
American Stroke Association
9%
Apixaban
9%
Anticoagulation Regimen
9%
Vascular Neurologist
9%
Medicine and Dentistry
Cohort Analysis
100%
Antithrombotic
100%
Vitamin K Antagonist
100%
Cerebral Venous Sinus Thrombosis
100%
Recanalization
25%
Major Bleeding
18%
Tertiary Care
12%
Bleeding
12%
Randomized Controlled Trial
12%
Anticoagulation
12%
Dabigatran
12%
Base
6%
Clinical Feature
6%
Medicine
6%
Apoplexy
6%
Lower Extremity Deep Vein Thrombosis
6%
Cerebral Hemorrhage
6%
Heparin
6%
Rivaroxaban
6%
Apixaban
6%
Cerebral Sinus Thrombosis
6%
Neuroscience
Antithrombotic
100%
Cohort Analysis
100%
Vitamin K Antagonist
100%
Cerebral Venous Sinus Thrombosis
100%
Randomized Controlled Trial
12%
Dabigatran
12%
Heparin
6%
Cerebral Hemorrhage
6%
Deep Vein Thrombosis
6%
Dural Venous Sinuses
6%
Rivaroxaban
6%
Cerebral Veins
6%
Apixaban
6%
Cerebrovascular Accident
6%